Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a pilot, 4-week, double-blind, placebo-controlled, randomized trial of individuals with alcohol use disorder (AUD) to receive weekly injections of either tirzepatide (n=10) or matching placebo (n=10). The primary aim is to determine the effects of tirzepatide on cue-reactivity among individuals with AUD. The secondary aim is to assess the safety and preliminary efficacy of tirzepatide for AUD.
Participants include N=20 men and women with DSM5 diagnosis of AUD. Potential participants will be screened and enrolled only if they meet full inclusion criteria. After screening and baseline procedures (Visit 1) are complete, participants will be randomized to receive either tirzepatide or placebo. Following randomization, participants will be scheduled for five study visits (Visits 2-6). Each visit will last approximately 1 hour, except for study visits 1 and 6 which will take no more than 3 hours in order to conduct additional neurocognitive testing, including cue-induced cravings and decision-making tests. At all study visits, participants will complete vital signs, weight, urine toxicology testing, a blood draw for glucose, and questionnaires probing secondary outcomes (i.e. anxiety and depression, suicidality, substance use, opioid withdrawal symptoms, cravings, etc). At study visits 2-5, the weekly dose of tirzepatide or placebo will be administered, and assessment of adverse events will also be completed. Both participants and study staff (including raters) will be blinded to active drug vs. placebo. At visit 1, subjects' expectations about their potential treatment will be queried. The final visit, visit 6, also called the follow-up visit, will also assess subjects' guess as to which treatment they received. The medication will be purchased from the manufacturer and stored by IDS. The IDS will extract the tirzepatide and draw the dose into syringes, which will match visually with the placebo doses.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tirzepatide | Experimental | This arm will receive tirzepatide (n=10) weekly 2.5mg injections for 4 weeks. |
|
| Saline Placebo | Placebo Comparator | This arm will receive saline placebo injections (n=10) weekly for 4 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tirzepatide | Drug | This intervention will consist of the FDA-approved dosing schedule. Participants will receive 2.5mg weekly injections for 4 weeks. IDS will extract tirzepatide and draw the doses into syringes. |
| Measure | Description | Time Frame |
|---|---|---|
| Cue-induced Cravings for Alcohol | Cue-induced craving scores at follow-up compared to baseline using a standard cue-reactivity paradigm utilizing visual cues. Cravings will be measured on a scale from 0-10 with 10 meaning extreme cravings. | Baseline visit and 5 weeks after baseline visit. |
| Incidence and Severity of Adverse Events | Study staff will be notified of any hospital admissions via Epic, and adverse events will be queried specifically using the Patient Rated Inventory of Side Effects (PRISE) at study weeks 2-5. The PRISE is a self-report tool to qualify side effects. For each domain, the patient indicates whether they have experienced certain symptoms and whether the symptoms are tolerable or distressing. | Epic monitoring throughout the trial and PRISE administered at study weeks 2-5 (visits 3-6). |
| Measure | Description | Time Frame |
|---|---|---|
| Penn Alcohol Craving Scale (PACS) | A self-report tool used to measure craving for alcohol during the past week. Participants respond to 5 questions on a scale of 0-6 for a total score of 0-30, with higher scores indicating stronger cravings. | At each study visit up to and including the final visit 5 weeks after baseline. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Joji Suzuki, MD | Contact | 617-732-5752 | jsuzuki2@bwh.harvard.edu | |
| Laura M Holsen, Ph.D. | Contact | 617-525-8772 | lholsen@bwh.harvard.edu |
| Name | Affiliation | Role |
|---|---|---|
| Joji Suzuki, MD | Brigham and Women's Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Brigham and Women's Hospital | Active, not recruiting | Boston | Massachusetts | 02115 | United States | |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000437 | Alcoholism |
| ID | Term |
|---|---|
| D019973 | Alcohol-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000098860 | Tirzepatide |
| ID | Term |
|---|---|
| D000067757 | Glucagon-Like Peptide-1 Receptor |
| D000067756 | Glucagon-Like Peptide Receptors |
| D043562 | Receptors, G-Protein-Coupled |
| D011956 | Receptors, Cell Surface |
Not provided
Not provided
Not provided
Not provided
Not provided
The IDS will perform both the randomization and blinding and will be the only unblinded research staff. They will extract the tirzepatide and draw the dose into syringes, which will match visually with the placebo doses. All other research staff will remain blinded for the duration of the trial.
|
| Saline Placebo | Other | Placebo syringes of saline and matching volume will be produced by IDS. |
|
| Monetary Choice Questionnaire (MCQ) |
A self-report tool used to measure delayed discounting. Participants will be asked to pick one of the two choices given. Score calculated typically falls between 0.0 and 0.5, with smaller values indicating a lack of discounting and preference for delayed rewards and higher values indicating strong discounting and a preference for immediate rewards. |
| Baseline visit and 5 weeks after baseline visit. |
| Visual Probe Task | A behavioral task to assess attentional bias. Alcohol-related and neutral images will be used, different from the ones used for the cue-reactivity paradigm to limit habituation. A pair of images will appear on the left and right of the screen for either a short (200ms) or long (500ms) stimulus duration to assess automatic orientating and controlled attention processing, respectively. Image pairs will be replaced by a probe in the location of either the opioid-related or neutral image. The probe will remain until the participant responds to identify the probe orientation by pressing the response keys as quickly as possible. This task will yield reaction times for analysis. | Baseline visit and 5 weeks after baseline visit. |
| Percent days abstinent | The percentage of days abstinent from alcohol, defined as 0 drinks on a given day, out of all days queried. The study investigators will use the Time-Line Follow Back (TLFB), a gold-standard method of evaluating substance use, as well as weekly urine toxicology screens. | At each study visit up to and including the final visit 5 weeks after baseline. |
| Percent heavy drinking days | Percentage of heavy drinking days, defined as 5 or more drinks in one day for males and 4 or more drinks in one day for females, out of all days queried. The study investigators will use the Time-Line Follow Back (TLFB), a gold-standard method of evaluating substance use, as well as weekly urine toxicology screens. | At each study visit up to and including the final visit 5 weeks after baseline. |
| Drinks per drinking day | The average number of drinks per drinking day. A drinking day is a day in which one or more alcoholic beverages were consumed. The study investigators will use the Time-Line Follow Back (TLFB), a gold-standard method of evaluating substance use, as well as weekly urine toxicology screens. | At each study visit up to and including the final visit 5 weeks after baseline. |
| Clinical Institute Withdrawal Assessment (CIWA) | Tool for assessing alcohol withdrawal. Scale of 0-67, with a higher number meaning more severe withdrawal. | At each study visit up to and including the final visit 5 weeks after baseline. |
| Blood Sugar | Blood glucose obtained via finger stick or blood already drawn for other tests. | At each study visit up to and including the final visit 5 weeks after baseline. |
| Hemoglobin A1c | Hemoglobin A1c obtained via blood draw. | Baseline and 5 weeks after baseline visit. |
| Weight | Weight measured in kilograms. | At each study visit up to and including the final visit 5 weeks after baseline. |
| Columbia Suicide Severity Rating Scale (C-SSRS) | A commonly used tool to assess suicidal ideation. The sum ranges from 2 to 25, with the higher number indicating more intense ideation. | At each study visit up to and including the final visit 5 weeks after baseline. |
| Patient Health Questionnaire-8 (PHQ-8) | A tool to assess depression symptoms. Scale of 0-24, with a higher score meaning more depression symptoms. | At each study visit up to and including the final visit 5 weeks after baseline. |
| Generalized Anxiety Disorder-7 (GAD-7) | A standard tool to assess anxiety symptoms. Scale of 0-21 with a higher number indicating more anxiety. | At each study visit up to and including the final visit 5 weeks after baseline. |
| Heart rate | Heart rate measured in beats per minute. | At each study visit up to and including the final visit 5 weeks after baseline. |
| Blood pressure | Blood pressure measured in systolic/diastolic (mmHg/mmHg). mmHg = millimeters of mercury. | At each study visit up to and including the final visit 5 weeks after baseline. |
| Assessment of Blind | Measure of participant perception of whether they received the active study drug. | 5 weeks after baseline visit. |
| Stanford Efficacy of Treatment Scale (SETS) | A tool for measuring patient outcome expectancy in clinical trials. | Baseline visit. |
| Fibrosis-4 (FIB-4) | A non-invasive measure of liver fibrosis. The higher the score, the more severe the fibrosis. | Baseline visit and 5 weeks after baseline visit. |
| Brigham and Women's Faulkner Hospital |
| Recruiting |
| Jamaica Plain |
| Massachusetts |
| 02130 |
| United States |
|
| D008565 | Membrane Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D011964 | Receptors, Gastrointestinal Hormone |
| D018000 | Receptors, Peptide |